BioMarin Pharmaceutical

Biomarin
Pharma

Trial results set up BioMarin for expansion of Voxzogo

With phase 3 results that have “exceeded” its expectations, BioMarin looks set up to gain a label expansion for dwarfism drug Voxzogo.
Kevin Dunleavy May 21, 2026 10:23am
reducing people on team

BioMarin lays off staffers at recently-acquired Amicus

May 12, 2026 5:12pm
Biomarin

BioMarin halts dosing, enrollment in 3 midstage Voxzogo studies

Mar 16, 2026 11:26am
Traffic light go start restart green light

FDA approves Ascendis' achondroplasia treatment Yuviwel

Mar 2, 2026 9:25am
Lifeline
Favicon Fierce Biotech

Midsize biotechs form coalition to fight against MFN policy

Feb 25, 2026 1:05pm
Biomarin

BioMarin pulls gene therapy Roctavian off the market

Feb 24, 2026 12:30pm